Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19371517 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | March 2026 | Allow | 4 | 0 | 0 | Yes | No |
| 19371529 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | March 2026 | Allow | 5 | 0 | 0 | Yes | No |
| 19350944 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | December 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19350939 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | February 2026 | Allow | 5 | 0 | 0 | Yes | No |
| 19350933 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | February 2026 | Allow | 5 | 0 | 0 | Yes | No |
| 19350713 | ADVANTAGEOUS MORPHIC FORM OF AT-527 HEMI-SULFATE SALT | October 2025 | March 2026 | Abandon | 5 | 1 | 0 | No | No |
| 19327711 | METHODS OF IMPROVING LUNG FUNCTION | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19327682 | METHODS OF IMPROVING LUNG FUNCTION | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19320020 | CHEMICAL COMPOUNDS AND USES THEREOF | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19317897 | METHOD FOR EXTRACTING UNFRACTIONATED HEPARIN FROM CAMEL INTESTINAL MUCOSA | September 2025 | January 2026 | Allow | 5 | 1 | 0 | No | No |
| 19315079 | S-BETA-HYDROXYBUTYRATE ESTERS FOR IMPROVING METABOLIC FUNCTION | August 2025 | January 2026 | Allow | 5 | 1 | 0 | No | No |
| 19312906 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | August 2025 | February 2026 | Allow | 6 | 0 | 0 | Yes | No |
| 19296535 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | August 2025 | December 2025 | Allow | 4 | 0 | 0 | No | No |
| 19295254 | FORMULATIONS OF VIMSELTINIB | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19286812 | Biphenyl and Phenylpyridine Compounds | July 2025 | December 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 19278338 | TOPICAL COMPOSITIONS | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19278422 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | July 2025 | February 2026 | Allow | 7 | 0 | 0 | Yes | No |
| 19278380 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | July 2025 | February 2026 | Allow | 7 | 0 | 0 | Yes | No |
| 19278356 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | July 2025 | January 2026 | Allow | 6 | 0 | 0 | Yes | No |
| 19272742 | PROCESS FOR REMOVING TIN OXIDE DEPOSITS | July 2025 | December 2025 | Allow | 5 | 1 | 0 | No | No |
| 19271553 | GLP-1R Agonist and Therapeutic Method Thereof | July 2025 | December 2025 | Allow | 5 | 0 | 1 | No | No |
| 19261853 | COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDS | July 2025 | December 2025 | Allow | 6 | 1 | 0 | No | No |
| 19261756 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | July 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19258578 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB | July 2025 | January 2026 | Allow | 6 | 1 | 0 | No | No |
| 19256777 | OCEANOBACILLUS JEDDAHENSE STRAIN HMF12 AND ITS APPLICATION | July 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19250968 | SOLID STATE FORMS | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19250765 | SOLID STATE FORMS | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19250795 | COMPOSITION | June 2025 | February 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 19249435 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19247553 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | June 2025 | July 2025 | Allow | 1 | 0 | 0 | No | No |
| 19242597 | CATALYTIC METHOD FOR ACRYLATE PRODUCTION | June 2025 | August 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19233768 | METHOD FOR PREPARING METHANOL BASED ON CARBON DIOXIDE CAPTURE, METHOD FOR PREPARING ETHYLENE GLYCOL AND ENVIRONMENT-FRIENDLY POLYESTER | June 2025 | January 2026 | Allow | 7 | 1 | 0 | No | No |
| 19230319 | DIPYRIDINE BENZOTHIOPHENE DERIVATIVE COMPOUND | June 2025 | July 2025 | Allow | 2 | 0 | 0 | No | No |
| 19230710 | Animal Feeds and Feed Premixes Containing Betaine and a Phytase | June 2025 | November 2025 | Allow | 5 | 1 | 0 | No | No |
| 19227609 | METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINE | June 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19227593 | METHOD FOR TREATING HIV WITH CABOTEGRAVIR AND RILPIVIRINE | June 2025 | January 2026 | Allow | 8 | 1 | 0 | No | No |
| 19224687 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | May 2025 | January 2026 | Allow | 7 | 0 | 1 | No | No |
| 19224601 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | May 2025 | November 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19223085 | METHOD FOR SEPARATING AMOXICILLIN AND PHENYLACETIC ACID FROM REACTION SOLUTION IN ONE-STEP ENZYMATIC SYNTHESIS OF AMOXICILLIN | May 2025 | July 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19219596 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | May 2025 | July 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19218087 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | May 2025 | August 2025 | Allow | 2 | 1 | 0 | Yes | No |
| 19217196 | METHOD OF DIMETHYL CARBONATE PRODUCTION | May 2025 | July 2025 | Allow | 2 | 0 | 0 | No | No |
| 19217261 | Biopreparation Against Ectoparasites of Cattle and Method of Application Thereof | May 2025 | September 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19215054 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19209549 | HEMOGLOBIN-BASED OXYGEN CARRIER COMPOSITIONS | May 2025 | February 2026 | Allow | 9 | 2 | 0 | No | No |
| 19207954 | SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOF | May 2025 | December 2025 | Allow | 7 | 0 | 0 | No | No |
| 19207485 | MIXED-METAL METAL ORGANIC FRAMEWORK | May 2025 | July 2025 | Allow | 2 | 1 | 0 | No | No |
| 19206909 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19205979 | APPLICATION OF GLYCEROL MONODECANOATE IN PREPARATION OF HYPOGLYCEMIC DRUG OR FUNCTIONAL FOOD | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19196922 | AZITHROMYCIN PREMIX FORMULATION AND PRODUCT, METHODS OF PREPARING SAME, AND METHODS OF USING SAME | May 2025 | September 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19197151 | SYNTHESIS OF NOVEL VANADIUM ALKYLIDYNE COMPLEXES AND THEIR USE IN METATHESIS REACTIONS | May 2025 | November 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 19193361 | NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF | April 2025 | January 2026 | Allow | 8 | 2 | 0 | No | No |
| 19189316 | ONE-STEP METHOD FOR SYNTHESIZING AMOXICILLIN FROM PENICILLIN OR SALT THEREOF THROUGH ENZYME CATALYSIS | April 2025 | September 2025 | Allow | 5 | 1 | 1 | No | No |
| 19186434 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OSTEOARTHRITIS | April 2025 | October 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19184071 | METHOD FOR SEPARATING AND PURIFYING FUCOIDAN | April 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19183918 | MODIFIED CELLULOSE AND THE PREPARATION METHOD AND APPLICATION THEREOF | April 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19180258 | APPARATUS AND METHODS USING TETHERED ENZYMES FOR THE DETECTION OF THE ENZYMATIC ACTIVITY OF BIOMARKERS | April 2025 | December 2025 | Abandon | 8 | 1 | 1 | No | No |
| 19175757 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | April 2025 | June 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19097967 | NITROGEN-DOPED CARBON-WRAPPED NICKEL CATALYST FOR SYNTHESIS OF HIGHER ALCOHOLS BY ASSEMBLY OF BIOETHANOL AND PREPARATION METHOD THEREFOR | April 2025 | November 2025 | Allow | 7 | 1 | 0 | No | No |
| 19094486 | AZAINDOLE ROCK INHIBITORS | March 2025 | May 2025 | Allow | 2 | 0 | 0 | No | No |
| 19092612 | PROCESSES FOR REMOVING CARBON DISULFIDE FROM SULFIDE PRODUCT STREAMS | March 2025 | December 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 19089839 | INHIBITORS OF NLRP3 INFLAMMASOME | March 2025 | October 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19084086 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | March 2025 | October 2025 | Allow | 7 | 1 | 0 | No | No |
| 19082283 | METHODS FOR TREATING CANCER, REDUCING SIDE EFFECTS OF CANCER TREATMENT, AND PREVENTING THE RECURRENCE OF CANCER | March 2025 | November 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19083391 | Olfactory Delivery Scaffold Compounds | March 2025 | January 2026 | Allow | 10 | 1 | 1 | No | No |
| 19079070 | FORMULATIONS OF VIMSELTINIB | March 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19075754 | TOPRAMEZONE DERIVATIVE AND USE THEREOF | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 19072846 | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF | March 2025 | July 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19072656 | KRAS INHIBITORS | March 2025 | December 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 19070439 | METHODS OF IMPROVING LUNG FUNCTION | March 2025 | August 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19069464 | Cannabichromene Derivatives And Use Thereof | March 2025 | July 2025 | Allow | 4 | 1 | 0 | No | No |
| 19067838 | QUATERNIZED CELLULOSE-BASED RESIN AND PREPARATION METHOD AND APPLICATION THEREOF | March 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19066352 | RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF | February 2025 | December 2025 | Allow | 10 | 2 | 0 | No | No |
| 19062521 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | February 2025 | June 2025 | Allow | 3 | 0 | 0 | No | No |
| 19061509 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | February 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19061577 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | February 2025 | May 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19059754 | Testosterone Dodecanoate Compositions and Methods | February 2025 | November 2025 | Allow | 9 | 2 | 0 | No | No |
| 19053800 | SYSTEM AND METHOD FOR GENERATING SYNTHETIC FUEL | February 2025 | July 2025 | Allow | 5 | 0 | 0 | No | No |
| 19050632 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | February 2025 | February 2026 | Abandon | 12 | 1 | 0 | No | No |
| 19048619 | USE OF PLATELET-BASED PRODUCTS FOR TREATMENT OF CAPSULAR CONTRACTURE PROXIMATE BREAST IMPLANT | February 2025 | September 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 19101657 | CONTINUOUS METHOD FOR PRODUCING N-BUTYL(METH)ACRYLATE INCLUDING A CATALYST RECIRCULATION PROCESS | February 2025 | November 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 19046435 | COMPOSITIONS AND METHODS FOR MINIMUM RISK PEST CONTROL | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19045102 | MEDICAL USE OF TAFOXIPARIN | February 2025 | July 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19042834 | Co3O4@C DERIVED FROM METAL-ORGANIC FRAMEWORKS USE FOR PRODUCTION OF METHYL ETHYL KETONE (MEK) | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19036816 | MULTIFUNCTIONAL LINKER COMPOUNDS | January 2025 | November 2025 | Allow | 9 | 2 | 0 | No | No |
| 19031698 | NICOTINAMIDE RIBOSIDE HYDROGEN MALATE CRYSTAL, AND ITS PREPARATION METHOD AND APPLICATION | January 2025 | April 2025 | Allow | 3 | 0 | 0 | No | No |
| 19026681 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS OF N-SULFONAMIDE AND USE THEREOF | January 2025 | February 2026 | Allow | 13 | 1 | 1 | Yes | No |
| 19030399 | AMINO ACID COMPOSITIONS | January 2025 | September 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 19030439 | AMINO ACID COMPOSITIONS | January 2025 | September 2025 | Allow | 8 | 1 | 0 | No | No |
| 19028631 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | January 2025 | May 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19030861 | TREATMENT OF IMMUNE DISORDERS | January 2025 | January 2026 | Allow | 12 | 1 | 0 | No | No |
| 19025101 | CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19023407 | ANTHRACENE-BASED COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF AS SOLAR THERMAL FUEL | January 2025 | April 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18995514 | Process For the Production of Methanol and Hydrogen from Methane Using a Solid Metal Hydroxide Reagent | January 2025 | June 2025 | Allow | 5 | 0 | 0 | No | No |
| 19021386 | METHOD FOR TREATING A DISORDER | January 2025 | August 2025 | Allow | 7 | 1 | 0 | No | No |
| 19022985 | METHODS FOR SEPARATING THE BINARY AZEOTROPIC MIXTURE OF ETHYLENE GLYCOL AND ETHYLENE GLYCOL DIACETATE WITH SULFOLANE ENTRAINER | January 2025 | August 2025 | Allow | 7 | 1 | 0 | No | No |
| 18994829 | Process For the Production of Dimethyl Ether and Hydrogen from Methane Using a Solid Metal Oxide Reagent | January 2025 | January 2026 | Abandon | 12 | 0 | 1 | No | No |
| 19021233 | PREPARATION METHOD OF BIOBASED ADIPIC ACID | January 2025 | February 2026 | Allow | 13 | 2 | 0 | Yes | No |
| 19022162 | PROTEOLYTIC ENZYME COMPOSITION | January 2025 | September 2025 | Allow | 8 | 2 | 0 | No | No |
| 19020241 | DOWNFLOW LIPID CONVERSION WITH UPFLOW CATALYST REGENERATION | January 2025 | May 2025 | Allow | 4 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1690.
With a 34.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Group 1690 is part of Technology Center 1600. This group has examined 8,374 patent applications in our dataset, with an overall allowance rate of 83.4%. Applications typically reach final disposition in approximately 32 months.
Applications in Group 1690 receive an average of 1.82 office actions before reaching final disposition. The median prosecution time is 32 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.